Stanford Medicine‘s history in cancer immunotherapy dates back to the 1980s – from researching personalized anticancer antibodies to treating pediatric leukemia with T-cells. More recently, Stanford scientists created a host of tools essential to new immunotherapy treatments. They shed light on T-cells, giving scientists a fresh look at the immune system through single-cell analysis and enable the mapping of regulatory DNA. This technology is being used across our research platform, driving PICI research forward. Crystal Mackall, MD | Director Mark Davis, PhD | Co-Director All Investigators Related Research Update Where Cancer-killing T-cells Come From Announcement PICI Young Investigator Retreat 2019 Research Update Predicting Childhood Leukemia Relapse Using Machine Learning Announcement Note from PICI’s President and CEO Jeff Bluestone: Introducing Our New Brand Clinical Trial The PORTER Trial Our Impact Informatics Accelerates the PRINCE Pancreatic Cancer Clinical Trial Our Impact PICI BioTrust Decodes Triple Negative Breast Cancer in TRIBUTE Collaboration Our Impact Improve Life After Cancer: Addressing Autoimmunity Partner Highlight Nonprofits Join Forces for a Cure: Cancer Research Institute